Last reviewed · How we verify
PF-06651600 Maintenance Dose #2
At a glance
| Generic name | PF-06651600 Maintenance Dose #2 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (PHASE2)
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata (PHASE3)
- A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects (PHASE2)
- PF-06651600 for the Treatment of Alopecia Areata (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06651600 Maintenance Dose #2 CI brief — competitive landscape report
- PF-06651600 Maintenance Dose #2 updates RSS · CI watch RSS
- Pfizer portfolio CI